MYGN Stock — Myriad Genetics Inc.: Cash, EV, Pipeline

What they do

We develop and commercialize molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs.

Source: 10-K FY2025 via SEC EDGAR

Share price

$5.92

Market cap

$566.2M

Cash

$115.2M

Enterprise value

$571.7M

Balance sheet

Cash	$115.2M
Debt	$120.7M
Net cash	-$5.5M
Enterprise value	$571.7M
Basic shares	95.6M shares
Fully diluted shares	103.4M shares
Fully diluted market cap	$612.4M
Cash per share	$1.20
Quarterly burn	$8.3M
Cash runway	13.9 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

95.6M

Pre-funded warrants

0.0M

Options

0.7M

RSUs

7.1M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

103.4M

Cap table as of 2025-12-31.

Price history

Loading MYGN daily closes…

Loading price history…

Next catalyst

SKB264 · Jan 11 - Feb 22 in 14 mo · Phase 2 · Solid Tumor

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 11 - Feb 22 in 14 mo	SKB264	Phase 2	Solid Tumor	—
Jan 12 - Feb 23 in 27 mo	Melphalan	Phase 1	Pancreatic Adenocarcinoma Metastatic; BRCA1 Mutation; BRCA2 Mutation	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Prolaris with PathomIQ AI

Approved · Active Modality: diagnostic (AI-enabled)

Partnerships PATHOMIQ Inc. (exclusive U.S. licensing rights to PATHOMIQ_PRAD AI-enabled diagnostic platform)

Indications

Prostate cancer (Approved)

Status note Launched May 2026. First prostate cancer test combining genomics and digital pathology AI.

FirstGene

Stage not disclosed · Active Modality: diagnostic

Indications

Cancer (Stage not disclosed)

Status note New test candidate in development; stage not disclosed.

Precise MRD

Stage not disclosed · Active Modality: diagnostic

Indications

Cancer (molecular residual disease) (Stage not disclosed)

Status note New test candidate in development; stage not disclosed.

Liquid biopsy companion diagnostic

Stage not disclosed · Active Modality: diagnostic (companion diagnostic)

Partnerships SOPHiA GENETICS S.A. (strategic collaboration, September 2025, to co-develop global liquid biopsy companion diagnostic solution for biopharmaceutical clinical programs and precision oncology)

Indications

Cancer (liquid biopsy) (Stage not disclosed)

Status note In co-development with SOPHiA GENETICS; stage not disclosed.

EndoPredict

Approved · Active Modality: diagnostic

Indications

Breast cancer (Approved)

Status note Company expects to discontinue sales of EndoPredict in the United States during the first half of 2026.

Per-asset detail extracted from the 10-Q filed 2026-07-31. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT02655016	Phase 3	Active, not recruiting	Collaborator	Tesaro, Inc.	—	Ovarian Neoplasms	—
NCT05642780	Phase 2	Active, not recruiting	Collaborator	Klus Pharma Inc.	—	Solid Tumor	—
NCT04150042	Phase 1	Recruiting	Collaborator	General Oncology, Inc.	—	Pancreatic Adenocarcinoma Metastatic; BRCA1 Mutation; BRCA2 Mutation	—
NCT07052266	Not disclosed	Recruiting	Collaborator	Weill Medical College of Cornell University	—	Hereditary Cancer Syndromes	—
NCT05457257	Not disclosed	Active, not recruiting	Collaborator	AZN	AZN, MRK	Metastatic Castration-resistant Prostate Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 5 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Tesaro, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	0	-125,000,000	0.00%	2026-08-14
Deerfield Management	0	-505	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

MYGN — Myriad Genetics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

MYGN — Myriad Genetics Inc.